|
UEVLD expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64446234407478E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.90834023530806E-12 |
| Normal-vs-Stage2 |
1.69869999999683E-06 |
| Normal-vs-Stage3 |
5.48929790511465E-11 |
| Normal-vs-Stage4 |
7.80719933146656E-11 |
| Stage1-vs-Stage2 |
5.952000E-01 |
| Stage1-vs-Stage3 |
3.984200E-01 |
| Stage1-vs-Stage4 |
1.002840E-01 |
| Stage2-vs-Stage3 |
3.001400E-01 |
| Stage2-vs-Stage4 |
8.092400E-02 |
| Stage3-vs-Stage4 |
3.647400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.96176408451265E-13 |
| Normal-vs-AfricanAmerican |
4.44689999999914E-05 |
| Normal-vs-Asian |
3.43479999997953E-09 |
| Caucasian-vs-AfricanAmerican |
6.668000E-01 |
| Caucasian-vs-Asian |
4.928600E-01 |
| AfricanAmerican-vs-Asian |
3.737200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.44182493406242E-13 |
| Normal-vs-Female |
2.40696351738734E-12 |
| Male-vs-Female |
1.759570E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.7336998503481E-10 |
| Normal-vs-Age(41-60Yrs) |
7.09143854749072E-12 |
| Normal-vs-Age(61-80Yrs) |
2.09600115042008E-11 |
| Normal-vs-Age(81-100Yrs) |
3.645600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.827600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.131400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.001400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.839200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.211400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.857600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.275200E-01 |
| Classical-VS-Follicular |
4.398000E-01 |
| Classical-VS-Other |
1.095030E-01 |
| Classical-VS-Normal |
5.74751357618197E-12 |
| Tall-VS-Follicular |
3.976400E-01 |
| Tall-VS-Other |
4.145800E-01 |
| Tall-VS-Normal |
6.44069999555796E-08 |
| Follicular-VS-Other |
2.400000E-01 |
| Follicular-VS-Normal |
6.99430002804036E-09 |
| Other-VS-Normal |
1.760660E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.30055990818801E-12 |
| Normal-vs-N1 |
2.31380026249894E-10 |
| N0-vs-N1 |
1.570210E-01 |
|
|
